Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles

Gastroenterology

Volumn 123, Issue 4, 2002, Pages 1238-1251

  Fickert, Peter ^a   Zollner, Gernot ^a   Fuchsbichler, Andrea ^a   Stumptner, Conny ^a   Weiglein, Andreas H ^a   Lammert, Frank ^b   Marschall, Hanns Ulrich ^c   Tsybrovskyy, Oleksiy ^a   Zatloukal, Kurt ^a   Denk, Helmut ^a   Trauner, Michael ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; GLYCOPROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN MDR2; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT DISEASE; BILE DUCT LIGATION; BILE DUCT OBSTRUCTION; BILE DUCT PRESSURE; BIOCHEMISTRY; CONTROLLED STUDY; ELECTRON MICROSCOPY; GENE DISRUPTION; INFARCTION; LIVER CELL; LIVER INJURY; MALE; MANOMETRY; MDR2 GENE; MORTALITY; MOUSE; NONHUMAN; PRESSURE MEASUREMENT; PRIORITY JOURNAL;

EID: 0036788262     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.35948     Document Type: Article

References (57)

1. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998;17:1217-1227.
2. Hofmann A. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999;159:2647-2658.
3. Kullack-Ublick GA, Meier PJ. Mechanisms of cholestasis. Clin Liver Dis 2000;4:375-385.
4. Trauner M, Graziadei IW. Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver disease. Aliment Pharmacol Ther 1999;13:979-996.
5. Poupon R, Poupon RE. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther 1995;66:1-15.
6. Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 1998;28:1449-1453.
7. Thompson JN, Cohen J, Blenkharn JI, McConnel JS, Barr J. A randomized trial of oral ursodeoxycholic acid in obstructive jaundice. Br J Surg 1986;73:634-636.
8. Hsu SH, Lu CL, Chan CYX, Chang FY, Lee SD. The effects of ursodeoxycholic acid in patients with severe obstructive jaundice after drainage procedure. Chung Hua I Hsue Tsa Chih 1997;60: 142-146.
9. Cahill CJ. Prevention of postoperative renal failure in patients with obstructive jaundice: the role of bile salts. Br J Surg 1983;70: 590-595.
10. Evans HJR, Torrealba V, Hudd C. The effect of preoperative bile salt administration on postoperative renal function in patients with obstructive jaundice. Br J Surg 1982;69:706-708.
11. Zimmermann H, Reichen J. Ursodeoxycholate has no beneficial effect on liver function or histology in biliary cirrhosis in the rat. J Hepatol 1992;16:355-359.
12. Poo JL, Feldmann G, Erlinger S, Braillon A, Gaudin C, Dumont M, Lebrec D. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Gastroenterology 1992;102:1752-1759.
13. Frezza EE, Gerunda GE, Plabani M, Galligioni A, Giacomini A, Neri D, Faccioli AM, Tiribelli C. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rats. Dig Dis Sci 1993;38:1291-1296.
14. Purucker E, Marschall HU, Winograd R, Matern S. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. Biochim Biophys Acta 2001; 1526:44-52.
15. Van Nieuwkerk CM, Oude Elferink RP, Groen AK, Ottenhoff R, Tytgat GN, Dingemans KP, Van Den Bergh Weerman MA, Offerhaus GJ. Effects of ursodeoxycholate and cholate feeding on liver diseases in FVB mice with disrupted mdr2 P-glycoprotein gene. Gastroenterology 1996;111:165-171.
16. Van Nieuwkerk CMJ, Groen AK, Ottenhoff R, van Wijland M, van den Bergh Weerman MA, Tytgat GN, Offerhaus JJ, Oude Elferink RP. The role of bile salt composition in liver pathology of mdr2 (-/-) mice: differences between males and females. J Hepatol 1997;26:138-145.
17. De Vree JML, Jaquemin E, Sturm E, Cresteil D, Bosna PJ, Aten J, Deluze JF, Desrochers M, Burdelski M, Bernard O, Oude Elferink RP. Mutations in the mdr3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 1998;95:282-287.
18. Jacquemin, E, De Vree JM, Cresteil D, Sokal EM, Sturm E, Dumont M, Scheffer GL, Paul M, Brudelski M, Bosma PJ, Bernard O, Hadchouel M, Oude Elferink RP. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001;120:1448-1458.
19. Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, Weaver J, Nelson-Piercy C, de Swiet M, Warens G, Elias E, Higgins CF, Johnston DG, McCarthy MI, Williamson C. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000;9:1209-1217.
20. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30:325-332.
21. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001;121:170-183.
22. Prieto J, Qian C, Garcia N, Diez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology 1993;105:572-578.
23. Medina JF, Martinez-Anso, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997;25:12-17.
24. Trauner M, Arrese M, Soroka CJ, Anathanarayanan M, Koeppel TA, Schlosser SF, Suchy FJ, Keppler D, Boyer JL. The rat canalicular conjugate export pump (Mrp2) is downregulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997; 113:255-264.
25. Roze C, Souchard M, de la Tour J, Vaille C, Debray C. Effects of selective biliary tract obstruction on the bile secretion in the rat. Biol Gastroenterol 1975;8:21-31.
26. Frijters CM, Ottenhoff R, van Wijland MJ, van Nieuwkerk CM, Oude Elferink RP. Regulation of mdr2 P-glycoprotein expression by bile salts. Biochem J 1997;321:389-395.
27. Wang DQ, Lammert F, Cohen DE, Paigen B, Carey MC. Cholic acid aids absorption, biliary secretion, and phase transitions of chotesterol in murine cholelithogenesis. Am J Physiol 1999;276: G751-G760.
28. Mendez-Sanchez N, Brink MA, Paigen B, Carey MC. Ursodeoxycholic acid and cholesterol induce enterohepatic cycling of bilirubin in rodents. Gastroenterology 1998;115:722-732.
29. Roda E, Azzaroli F, Nigro G, Piazza F, Ferrara F, Liva S, Giovanelli S, Miracolo A, Colecchia A, Festi D, Roda A, Mazzella G. Greater biliary enrichment and improved liver tests with higher doses of ursodeoxycholic acid in primary biliary cirrhosis (abstr). Gastroenterology 2001;121(Suppl 1):A-574.
30. Voshol PJ, Havinga R, Wolters H, Ottenhoff R, Princen HM, Oude RP, Groen AK, Kuipers F. Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology 1998;114:1024-1034.
31. Marschall HU, Broomé U, Einarsson C, Alvelius G, Thomas HG, Matern S. Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis. J Lipid Res 2001;42:735- 742.
32. Krienen H, Notermans P, Passia D, Hofmann N. Über die Herstellung und Untersuchung von Ausgusspraeparaten mit Plastogen G. Der Präparator 1981;27:109-113.
33. Popper H, Kent G, Stein R. Ductular cell reaction in the liver in hepatic injury. J Mt Sinai Hosp 1957;24:551-556.
34. Alpini G, Ueno Y, Glaser SS, Marzioni M, Phinyzi JL, Francis H, LeSage G. Bile acid feeding increased proliferative activity and apical bile acid transporter expression in both small and large cholangiocytes. Hepatology 2001;34:868-876.
35. Wiener SM, Hoyt RF, Deleonardis JR, Clevenger RR, Jeffries KR, Nagashima K, Mandel M, Owens J, Eckhausen M, Lutz RJ, Safer B. Manometric changes during retrograde biliary infusion in mice. Am J Physiol 2000;279:G49-G66.
36. Marshman E, Ottewell PD, Potter CS, Watson AJ. Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine. J Pathol 2001;195:285-292.
37. Caulin C, Ware CF, Magin TM, Oshima RG. Keratin-dependent, epithelial resistance to tumor necrosis factor-induced apoptosis. J Cell Biol 2000;149:17-22.
38. Liao J, Ku NO, Omary MB. Stress, apoptosis, and mitosis induce phosphorylation of human keratin 8 at ser-73 in tissues and cultured cells. J Biol Chem 1997;272:17565-17573.
39. MacFarlan M, Merrison W, Dinskale D, Cohen MG. Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. J Cell Biol 2000; 148:1239-1254.
40. Gilbert S, Loranger A, Daigle N, Marceau N. Simple epithelium keratins 8 and 18 provide resistance to FAS-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J Cell Biol 2001;154:763-773.
41. Redondo C, Flores J, Gonzalez A, Nagata S, Carrera AC, Merida J, Martinez AC. Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. J Clin Invest 1996;98:1245-1252.
42. Snijders AB, Bosker RJ. Multilevel analysis: an introduction to basic and advanced multilevel modeling. London: Sage Publishers, 1999.
43. Theise ND, Saxena R, Portmann BC, Thung SN, Yee H, Chriboga L, Kumar A, Crawford JM. The canals of Hering and hepatic stem cells in humans. Hepatology 1999;30:1425-1433.
44. Slott PA, Lin MH, Tavoloni N. Origin, pattern and mechanism of bile duct proliferation following biliary obstruction in the rat. Gastroenterology 1990;99:466-477.
45. Fickert P, Trauner M, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H. Cytokeratins as targets for bile acid-induced toxicity. Am J Pathol 2002;160:491-499.
46. Miyoshi H, Rust C, Roberts PJ, Brugart LJ, Gores GJ. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 1999;117:669-677.
47. Smitt JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, van der Valk MA, Offerhaus GJA, Berns AJM, Borst P. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-462.
48. Mauad TH, van Niewkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994;145:1237-1245.
49. Oude Elferink RP, Ottenhoff R, van Wijland M, Smitt JJ, Schinkel A, Groen AK. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest 1995;95:31-38.
50. Trauner M, Boyer JL. Cholestatic syndromes. Curr Opin Gastroenterol 2001;17:242-256.
51. Anderson JM. Leaky junctions and cholestasis: a tight correlation. Gastroenterology 1996;110:1662-1665.
52. Alpini G, Baiocchi L, Glaser S, Ueno Y, Marzioni M, Francis H, Phinizy JL, Angelico M, Lesage G. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology 2002;35: 1041-1052.
53. Mitchel SA, Bansi DS, Hunt N, Van Bergmann K, Flemming KA, Chapmann RW. A preliminary trial of high-dose ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 2001;124: 900-907.
54. Angulo P, Jorgensen RA, Lindor KD. Incomplete response to ursodeoxycholic acid: is a double dosage worthwhile? Am J Gastroenterol 2001;96:3152-3157.
55. Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S, Theilmann L. Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997;26: 560-566.
56. Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001;53: 308-312.
57. Lindor KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-695.